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North: MDL Remands: A Defense Perspective

MDL REMANDS: A DEFENSE PERSPECTIVE
Richard B. North, Jr.*
In their cartographic efforts, attorneys Ryan Hudson, Rex Sharp, and Dean
Nancy Levit understandably identify “remand” as one of the five stages of a
multidistrict litigation (MDL). However, including remand in their visual
depiction of the MDL process is tantamount to including Antarctica on a world
map; it is acknowledging a place generally known to most lawyers, but an area
where most attorneys–even experienced MDL practitioners–have seldom traveled.
But that may be changing. In recent years, a number of scholars, and even
some federal judges, have begun advocating for the more frequent remand of
individual MDL cases. And some judges are heeding that call. Over the last several
years, Judge Joseph R. Goodwin has remanded1 dozens of cases from the sprawling
pelvic mesh MDLs he has been handling in the Southern District of West Virginia.
More recently, Judge David G. Campbell from the District of Arizona has
remanded more than 2,000 cases from the In re: Bard IVC Filters MDL.
The advocates for remand advance a number of benefits that, in their view,
would result from the more frequent remand of MDL cases to other district courts
for trial. As a defense lawyer toiling in the trenches of an MDL and handling
numerous remanded (or transferred) cases, I am particularly interested in the belief
proposed by some that routinely remanding MDL actions may provide a
disincentive to the proliferation of meritless claims. This article briefly details the
trend toward remand, the theory that remands may discourage the filing of
marginal claims, and then provides some anecdotal evidence of how that
disincentive may actually exist.
I. THE TREND TOWARD REMAND
The genesis of any MDL is 28 U.S.C. § 1407. The provision contemplates
the transfer of related cases to a single judge, but not for ultimate resolution.2
Instead, the statutory language suggests limitations on a transferee judge’s role,
explicitly permitting transfer only for “coordinated or consolidated pre-trial
proceedings.”3 The provision further commands that “[e]ach action so transferred
shall be remanded by the panel at or before the conclusion of such pretrial
proceedings to the district from which it was transferred unless it shall have been
previously terminated.”4 And the Supreme Court has made clear that the plain
* The author wishes to thank Christopher Shaun Polston, his colleague at Nelson Mullins Riley &
Scarborough, LLP, for his invaluable assistance.
1
The term “remand” is technically a misnomer when used to describe many of the cases sent by
MDL judges to other courts. After the formation of an MDL and the transfer of cases to that court by
the Judicial Panel on Multidistrict Litigation (JPML), many MDL courts permit the direct filing of
additional cases in the transferee jurisdiction. When the time comes for remand, the directly filed
cases are typically transferred to other jurisdictions under 28 U.S.C. § 1404.
2
See 28 U.S.C. § 1407.
3
See id. § 1407(a).
4
Id. (emphasis added).
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language of the statute means what it says.5 The JPML may not decline to remand
a transferred case, over a party’s objection, once pretrial proceedings have been
completed.6
Despite the clarity of the statute’s wording and the Supreme Court’s
pronouncement, the historical reality is that remand of an MDL case is a rare
occurrence. According to the Administrative Office of the United States Courts,
since the JPML’s creation in 1968, only 2.3% of transferred cases have been
remanded (based on data collected as of September 30, 2019).7 However, that
number is misleading. It does not include the hundreds of thousands of additional
cases directly filed in MDLs that are never transferred out of the proceeding. If
the direct-filed cases were added to the calculation, the true percentage of MDL
cases ultimately transferred or remanded out of an MDL for trial is probably far
less than 1%. The rarity of MDL remands over the years can be explained by
many factors. Judge Eduardo Robreno, who ultimately supervised the epic
asbestos MDL, once observed: “[a]s a matter of judicial culture, remanding cases
is viewed as an acknowledgment that the MDL judge has failed to resolve the
case . . . .”8
More recently, however, the imperative for global resolution of MDL
litigation under the stewardship of a transferee judge appears to be receding. A
number of noted scholars have championed the perceived benefits of remanding
MDL cases for trial.9 Judge Clay D. Land, the former Chief Judge of the Middle
District of Georgia and a veteran transferee judge of two MDLs, has advocated
for the remand of MDL cases for case-specific discovery and adjudication
following the completion of pretrial proceedings regarding common issues, while
noting that his view is a “minority approach.”10
The proponents of remand identify many reasons for their viewpoint.
Among other things, they argue that the pursuit of global settlements and the
avoidance of remands benefit lead plaintiffs’ attorneys, sometimes at the expense
of plaintiffs with stronger claims.11 Some supporters of remands perceive

See Lexecon Inc. v. Milberg Weiss Bershad Hynes & Lerach, 523 U.S. 26, 35-36 (1998).
See id. at 34.
7
See Admin. Office of the U.S. Courts, Judicial Panel on Multidistrict Litigation—Judicial Business
2019 (2019), https://www.uscourts.gov/judicial-panel-multidistrict-litigation-judicial-business-2019
(“Since its creation in 1968, the Panel has centralized 722,146 civil actions for pretrial proceedings.
By the end of fiscal year 2019, a total of 16,918 actions had been remanded for trial. 570,766 actions
had been terminated in the transferee courts, and 134,462 actions were pending throughout 51
transferee district courts.”).
8
See Eduardo C. Robreno, The Federal Asbestos Product Liability Multidistrict Litigation (MDL875): Black Hole or New Paradigm?, 23 WIDENER L.J. 97, 144 (2013).
9
See, e.g., Elizabeth Chamblee Burch, Remanding Multidistrict Litigation, 75 LA. L. REV. 399
(2014); Georgene Vairo, Lessons Learned by the Reporter: Is Disaggregation the Answer to the
Asbestos Mess?, 88 TUL. L. REV. 1039, 1070 (2014).
10
See Clay D. Land, Multidistrict Litigation After 50 Years: A Minority Perspective from the
Trenches, 53 GA. L. REV. 1237, 1242 (2019).
11
See Elizabeth Chamblee Burch, Monopolies in Multidistrict Litigation, 70 VAN. L. REV. 67, 15254 (2017).
5
6
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advantages in having disputes resolved closer to a plaintiff’s home, by a judge
more familiar with the applicable state law.12
II. THE PROBLEM OF MARGINAL CLAIMS
Of particular interest to me, as a defense practitioner, is the widespread
belief that making MDL remand the norm will become a disincentive to the filing
of frivolous claims. The proliferation of marginal claims in the MDL setting is a
very real problem. An MDL subcommittee of the Advisory Committee for the
Rules of Civil Procedure has noted that there is “fairly widespread agreement”
among MDL stakeholders (experienced practitioners and judges alike) that the
problem exists.13 That committee estimates that 20-30% of claims in some
centralized proceedings, and perhaps as high as 40-50% of cases, are
“unsupportable.”14 Those marginal claims include cases where the plaintiff did not
use the product at issue or did not actually suffer an injury from the product, and
cases clearly barred by the statute of limitations.15 Judge Land has characterized
the phenomenon as one of the “unintended consequences” of MDL
consolidation.16 As he has observed, “[s]ome lawyers seem to think that their case
will be swept into the MDL where a global settlement will be reached, allowing
them to obtain a recovery without the individual merit of their case being
scrutinized as closely as it would if it proceeded as a separate individual action.”17
A number of commentators have referred to the proliferation of dubious claims in
an MDL proceeding as the “‘Field of Dreams’ problem – ‘if you build it, they will
come.’”18
One factor explaining the large number of questionable claims that often
populate MDLs is the staggering expansion of attorney advertising. The United
States Chamber Institute for Legal Reform, an affiliate of the United States
Chamber of Commerce, estimates that plaintiffs’ attorneys (in coordination with
lead generators and third-party financing groups) spend approximately $1 billion
annually on television advertising to solicit clients for mass tort litigation.19
See Land, supra note 10, at 1244.
ADVISORY COMM. ON RULES OF CIVIL PROCEDURE, MDL SUBCOMMITTEE REPORT 142-43 (Nov. 1,
2018), https://www.uscourts.gov/sites/default/files/2018-11_civil_rules_agenda_book_0.pdf.
14
Id. at 142.
15
Id.
16
See In re Mentor Corp. Obtape Transobturator Sling Prods. Liab. Litig., No. 4:08-MD-2004 (CDL),
2016 WL 4705827, at *1 (M.D. Ga. Sept. 7, 2016).
17
Id.
18
Burch, supra note 9, at 413-14; ADVISORY COMM. ON RULES OF CIVIL PROCEDURE, supra note 13,
at 142-43.
19
See U.S. CHAMBER INSTITUTE FOR LEGAL REFORM, GAMING THE SYSTEM: HOW LAWSUIT
ADVERTISING
DRIVES
THE
LITIGATION
LIFECYCLE
1
(2020),
https://www.instituteforlegalreform.com/uploads/sites/1/Gaming_the_System_How_Lawsuit_Adve
rtising_Drives_Litigation_Lifecycle_2020April.pdf. In its case study, the Institute found that
plaintiffs’ interests spent $94 million for advertising in the Pradaxa litigation; $122 million in the
Xarelto litigation; $63 million in talcum powder litigation; and $103 million in the Roundup
litigation. See id. at 2-3. Similarly, more than $89 million has been spent in advertising for cases
12
13
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Pervasive advertising of that magnitude attracts many plaintiffs whose claims are
then filed in an MDL in the hope that these potentially weaker claims will be
wrapped up in a global settlement, with the merits of the claims never examined.20
III. A REPORT FROM THE TRENCHES
Will the more frequent remand of MDL cases reduce the number of
doubtful claims filed? In the past, remand has occurred too rarely to provide any
robust data for assessing that proposition. My anecdotal experiences, however,
suggest that remand can indeed be a disincentive as theorized.
At present, my law firm (in coordination with other firms) is engaged in
the defense of hundreds of MDL cases that have been remanded from an MDL
concerning a medical device. Thus far, roughly twenty-five percent of the original
inventory of MDL cases have been sent to courts throughout the country. The
remanded cases undeniably include some claims which, although vigorously
contested, are by no means frivolous. A number of those plaintiffs are represented
by knowledgeable and diligent counsel. On the other side of the spectrum, the
remand process has exposed a significant number of cases that are marginal, at
best. Some of those plaintiffs are represented by counsel who are either illequipped or disinterested in actually litigating the case.
Some proponents have theorized that more frequent remands would result
in the dismissal of weak claims if plaintiffs’ attorneys could not hide their lack of
merit in an undifferentiated mass settlement.21 That prediction has come to fruition
in the litigation we are handling. Approximately ten percent of the remanded cases
have been dismissed within weeks or just a few months of remand, without any
settlement. In other words, the plaintiffs’ attorneys appear to have abandoned ten
percent of the remanded cases rather than choosing to prosecute them.
Proponents of remand have similarly speculated that the absence of a
global settlement may prompt some attorneys to withdraw from representation

against the various manufacturers of inferior vena cava filters (a figure determined by surveys
conducted by X Ante using Kantar CMAG data). Some plaintiffs’ attorneys have even continued to
spend millions of dollars on advertising during the COVID-19 pandemic after being approved for as
much as $49.7 million in loans from the Paycheck Protection Program according to data from the
United States Small Business Administration and surveys conducted by X Ante. See Nate Raymond,
Mass Tort Law Firms Spending Big on TV Ads Got U.S. Government Coronavirus Aid, REUTERS
LEGAL (July 24, 2020 12:07 AM), https://www.reuters.com/article/lawyers-advertising/mass-tortlaw-firms-spending-big-on-tv-ads-got-us-government-coronavirus-aid-idUSL2N2EV0LP.
20
See In re Mentor Corp. Obtape Transobturator Sling Prods. Liab. Litig., 2016 WL 4705827, at *1
n.2 (noting that “onslaught of lawyer television solicitations” contributed to an explosion of cases in
that MDL); ADVISORY COMM. ON RULES OF CIVIL PROCEDURE, supra note 13, at 142-43; accord
Douglas G. Smith, The Myth of Settlement in MDL Proceedings, 107 KY. L.J. 467, 471-72 (2019)
(noting MDL “[a]ggregation tends to encourage the filing of meritless claims for a variety of reasons,
including the reduction of individual scrutiny received by claims that are pending in aggregated
proceedings. As a result, there are many instances in which multidistrict litigations have been
inundated with claims that have later been eliminated because they lacked merit.”).
21
See, e.g., Burch, supra note 9, at 413-14; Land, supra note 10, at 1241 n.19.
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rather than litigate the case.22 Again, our experience has shown that concern to be
justified. We have seen dozens of instances where a plaintiff’s attorney has
withdrawn after remand, abandoning his or her client to navigate the litigation pro
se.
For those cases that have proceeded after remand, initial case-specific
discovery has exposed the problematic impact of television advertising. Many
plaintiffs admit, when deposed, that they never had any symptom or known
complication until they saw a television advertisement providing dire warnings
about the severe “risks” allegedly associated with the device. These plaintiffs often
complain about their fears that a complication will occur in the future, fears
associated more with the television solicitations (disguised as medical alerts) than
with any actual medical diagnosis.23 In those instances, the remands have led to
the case-specific discovery that has exposed the dubious nature of the claim.
Perhaps most disturbing, the remand process has exposed a few plaintiffs’
attorneys who are either ill-equipped or unwilling to handle the cases once
remanded.24 In some instances, attorneys have simply ignored orders scheduling
conferences or hearings, and failed to attend without any explanation. In other
cases, they have flouted local rules governing pro hac appearances and the
association of local counsel, sometimes to the irritation of the remand court.
Moreover, a number of plaintiffs’ attorneys–while striving to represent their clients
appropriately–simply have no familiarity with the history of the MDL or the
discovery that has previously occurred.
Despite the anecdotal evidence suggesting that remands can expose and
even sometimes eliminate marginal claims, remands are not a panacea for
defendants. Not surprisingly, remands can be costly. Significant funds and
resources are required to defend hundreds of cases simultaneously in courts
throughout the country. And remands can prolong and even increase the risks to
defendants, risks that global settlements are designed to control. In short, a remand
process is not advantageous to a defendant in every situation, as the costs may
sometimes outweigh the benefits. Stated differently, although remands may help
to cull meritless or marginal claims, the cost in many instances will simply be too
high.

See, e.g., Land, supra note 10, at 1241 n.19.
See generally Elizabeth Tippett, Medical Advice from Lawyers: A Content Analysis of Advertising
for Drug Injury Lawsuits, 41 AM. J.L. & MED. 7, 7 (2015) (studying sample television solicitations
in drug and device litigation, some of which “mimicked public service announcements, claiming to
be a ‘medical alert’ ‘consumer alert’ or ‘FDA warning’”); Daniel M. Schaffzin, Warning: Lawyer
Advertising May Be Hazardous to Your Health! A Call to Fairly Balance Solicitation of Clients in
Pharmaceutical Litigation, 8 CHARLESTON L. REV. 319, 327-41 (2013-2014) (discussing
proliferation of television solicitations and their marketing tactics).
24
The phenomenon is not unique to the litigation we are handling. Courts presiding over remanded
cases in other litigation have recently sanctioned plaintiffs’ attorneys for the mishandling of a case.
See Thompson v. C.R. Bard, Inc., No. 6:19-CV-17, 2020 WL 3052227, at *1 (S.D. Ga. June 8, 2020);
Rolandson v. Ethicon, Inc., No. 15-CV-537 (ECT/DTS), 2020 WL 2086279, at *10 (D. Minn. Apr.
30, 2020).
22
23
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IV. CONCLUSION
As long as television advertising for mass tort claimants continues
unabated, the proliferation of frivolous claims will undoubtedly remain a problem.
Courts, advisory committees, and commentators will continue to evaluate and
debate mechanisms to screen MDL case inventories for marginal claims. As that
debate proceeds, more frequent remands may emerge as a viable screening tool
and a disincentive for the filing of questionable claims. From our anecdotal
experiences in the trenches, remands do indeed appear to have that desired effect.
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